仙台病毒Tianjin株及其HN／F基因真核表达质粒对人副流感病毒I型的血清中和实验研究

目的：探讨仙台病毒Tianjin株（SeV）及其核酸制备预防人副流感病毒I型（hPIV—1）疫苗的可行性。方法：（1）用sev免疫小鼠3次后取血清，间接ELISA法检测免疫血清抗体效价。（2）将倍比稀释的免疫血清与100TCID~0．1ml的hPIV一1进行中和实验，观察细胞病变（CPE）并计算50％血清中和终点。（3）构建SeV真核表达质粒pVAX1-F、DVAX1-HN，分别单独或联合免疫小鼠，取免疫血清检测对hPIV一1的中和终点。结果：SeV免疫血清抗体的50％中和终点分别为39．8、12．6、16．0、44．7、25．1；质粒免疫血清抗体的中和作用按pVAX1-HN＋pVAX1-F组〉pVAX1-HN组〉DVAX1-F组依次递减。结论：仙台病毒Tianjin株及其HN基因、F基因真核表达质粒能诱导机体产生抗hPIV-1抗体，有可能成为制备预防hPIV-1疫苗的有效毒株。

Neutralization tests of Sendai virus,strain Tianjin and its HN/F gene eukaryotic expression plasmid to hPIV-1

Objective： To explore the potentiality of Sendai virus, strain Tianjin （SeV） and its nucleic acid used to prepare vaccines of human parainfluenza virus I （hPIV-1）. Methods： （1） Mice of 3 weeks old were immunized with SeV for 3 times. Sera were isolated and the SeV-specific antibodies were tested by indirect ELISA. （2） Neutralization tests were done with the immune sera and hPIV-1, then CPE was observed and 50% serum neutralization terminations were counted. （3） Eukaryotic expression plasmid pVAX1-F, pVAX1-HN of SeV were constructed. They were used in combination or single to immune mice and serum neutralization terminations were tested. Results： 50% serum neutralization terminations of SeV were 3 9.8, 12.6, 16.0, 44.7, 25.1, which of eukaryotic expression plasmid were decreased according to pVAX1 -HN ＋pVAX1 -F group 〉pVAXI -HN group 〉pVAX1 -F group. Conclusion： Sendai virus, strain Tianjin and its HN/F gene eukaryotic expression plasmid can induce the production of hPIV-1 antibodies, and then Sendai virus, strain Tianjin could be considered as a candidate strain to prepare the hPIV-1! vaccine.